NOVOCART 3D is part of a U.S. Food and Drug Administration Investigational New Drug Phase 3 randomized, multicenter study. The product is a matrix-induced autologous chondrocyte product, designed to repair articular cartilage defects of the knee.
Kenneth R. Zaslav, MD, an orthopedic surgeon with Advanced Orthopedics in Richmond, Va., performed the implantation during a knee surgery.
Aesculap Biologics, a division of Aesculap, is focused on biological approaches for the repair and regeneration of diseased or damaged tissues.
More articles on devices:
8 things to know about the Asia-Pacific minimally invasive spine device market
15 spine devices receive FDA 510(k) clearance in August
Former ArthroCare execs get 10+ years in prison for fraud costing shareholders $750M
